Aptevo Therapeutics (APVO) Current Deferred Revenue (2015 - 2017)
Aptevo Therapeutics (APVO) posted Current Deferred Revenue of $3.7 million for Q3 2017, up 156.23% sequentially from $1.4 million in Q2 2017, and up 478.12% YoY from $640000.0 in Q3 2016.
Aptevo Therapeutics (APVO) Current Deferred Revenue (2015 - 2017) Analysis & Trends
Aptevo Therapeutics has reported Current Deferred Revenue for 3 years, with the latest figure at $3.7 million in Q3 2017.
- Quarterly Current Deferred Revenue rose 478.12% year-over-year to $3.7 million in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $3.7 million (up 478.12% YoY) and the FY2016 annual result came in at $811000.0, down 78.9% from the prior year.
- Current Deferred Revenue improved to $3.7 million in Q3 2017 per APVO's latest filing, from $1.4 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $3.8 million in Q4 2015 and troughed at $394000.0 in Q2 2016.
- A 3-year average of $1.7 million and a median of $878000.0 in 2017 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2016 and 2017: Current Deferred Revenue plunged 78.9% in 2016, then jumped 478.12% in 2017.
- Over 3 years, Current Deferred Revenue stood at $3.8 million in 2015, then slumped by 78.9% to $811000.0 in 2016, then soared by 356.23% to $3.7 million in 2017.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $3.7 million, $1.4 million, and $878000.0 for Q3 2017, Q2 2017, and Q1 2017 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 3.70 Mn |
| Jun 30, 2017 | 1.44 Mn |
| Mar 31, 2017 | 878,000.00 |
| Dec 31, 2016 | 811,000.00 |
| Sep 30, 2016 | 640,000.00 |
| Jun 30, 2016 | 394,000.00 |
| Dec 31, 2015 | 3.84 Mn |